Demonstration Formulary
PALLIATIVE CARE PHYSICIANS - Guidelines for the use of drugs in symptom control
| Atomoxetine Strattera® |
|
Formulary
|
Please note that commissioning discussion is underway. However the present status is as follows:-
|
 ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Atomoxetine ESCA: Atomoxetine - Birmingham and Solihull practices TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
|
Age under 16 - Birmingham practices| Dexamfetamine |
|
Formulary
|
Please note that commissioning discussion is underway. However the present status is as follows:-
|
|
ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Dexamfetamine ESCA: Dexamfetamine (as Amfexa®) TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
|
| Guanfacine Intuniv® |
|
Formulary
|
For the treatment of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective |
|
| Lisdexamphetamine Elvanse® |
|
Formulary
|
Please note that commissioning discussion is underway. However the present status is as follows:-
|
|
ESCA: Lisdexamphetamine NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management |
|
|
| Methylphenidate |
|
Formulary
|
Please note that commissioning discussion is underway. However the present status is as follows:-
|
ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Methylphenidate ESCA: Methylphenidate NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents UKMI Q&A: Methylphenidate for adults with ADHD |
|
|
| Methylphenidate |
|
Formulary
|
Please note that commissioning discussion is underway. However the present status is as follows:-
The immediate release preparation may be prescribed generically |
|
ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Methylphenidate ESCA: Methylphenidate NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents UKMI Q&A: Methylphenidate for adults with ADHD |
|
|
| Modafinil |
|
Formulary
|
|
|
NICE: Evidence Summary (Apr 2013) |
|
| Solriamfetol Sunosi® |
|
Formulary
|
In line with NICE |
|
NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy |
|
|
Links
- Administration of depot antipsychotic injections during COVID-19 in stable adult patients
- ESCA: Atomoxetine - Birmingham and Solihull practices
- ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Atomoxetine
- ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Dexamfetamine
- ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Methylphenidate
- ESCA: Black Country - For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Methylphenidate
- ESCA: Dexamfetamine (as Amfexa®)
- ESCA: Lisdexamphetamine
- ESCA: Methylphenidate
- ESCA: Methylphenidate
- NICE CG72: Attention deficit hyperactivity disorder (ADHD)
- NICE NG87: Attention deficit hyperactivity disorder (ADHD): diagnosis and management
- NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management
- NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
- NICE TA98: Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine
- NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- NICE: Evidence Summary (Apr 2013)
- Shared care documents from Black Country Partnership NHS FT
- TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- UKMI Q&A: Attention deficit hyperactivity disorder (ADHD): diagnosis and management
- UKMI Q&A: Can methylphenidate be used for adults with ADHD?
- UKMi Q&A: Fish oil preparations - is there evidence that they improve concentration and behaviour in children?
- UKMI Q&A: Methylphenidate for adults with ADHD
- UKMI Q&A: Methylphenidate for adults with ADHD